Skip to main content

Lilly’s ambitious diabetes drug Mounjaro fails to impress in the fourth quarter

The new Type 2 diabetes treatment may be in high demand, but sales came in far below Wall Street’s expectations.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.